Share price movements

On April 30, Pfizer (PFE) reported first-quarter results. The company reported revenues of $13.12 billion in the first quarter, a YoY rise of 2% on a reported basis and 5% on an operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by 8% YoY volume growth but partly offset by a 3% drop in pricing.

In the first quarter, Pfizer reported GAAP EPS of $0.68, a YoY rise of 15.25%. The company reported non-GAAP EPS of $0.85, a YoY rise of 10.39% on a reported basis.

What Are Analysts Recommending for PFE after Q1 Results?

Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Pfizer surpassed consensus revenue estimates by $110 million and the consensus EPS estimate by $0.10 in the first quarter. After the results, Pfizer closed at $40.61 on April 30, 2.58% higher than the previous close, 18.16% higher than the 52-week low of $34.37, and 12.61% lower than the 52-week high of $46.47. The company’s market capitalization was $235.17 billion and PE, forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 23.62x, 13.26x, 4.38x, 3.71x, and 12.49x, respectively. On May 1, the stock closed at $40.77, 0.39% higher than the previous close.

On April 30, Pfizer’s 14-day RSI (relative strength index) was 44.98. The number of outstanding shares for the company is 5.79 billion, while the short float ratio is 2.77%.

Analysts’ recommendations and target price

Wall Street analysts expect upside potential of 8.52% for Pfizer based on the company’s closing price on April 30. Analysts have changed the company’s 12-month consensus target price from $44.54 in January to $44.14 in February to $44.36 in March and then to $44.07 in April.

Out of 15 analysts covering Pfizer, two analysts recommend a  “strong buy,” five recommend a “buy,” seven recommend a “hold,” and one recommends a “strong sell.” The consensus recommendation for the company is “hold.”

Latest articles

Marathon Petroleum (MPC) stock has been tumbling in Q3, driven by geopolitical tensions, oil price uncertainty, and weaker refining conditions.

This week, AT&T CEO Randall Stephenson noted that AT&T (T) is on track to reduce its leverage multiple to about 2.5x by the end of this year.

Jeff Bezos announced that Amazon had placed an order of 100,000 electric delivery vans from Michigan-based startup Rivian.

Bad news on the trade war front appears to have led to a fall in the broader US equity markets today. Cannabis ETFs were also trading in the red.

Energy Transfer (ET) stock has recovered in the last two trading sessions after investors hammered it on its plans to acquire SemGroup (SEMG).

Software-as-a-service company Datadog (DDOG) made a smashing debut on Wall Street yesterday. After its IPO, DDOG's shares surged 40% in intraday trading.